The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail

Pathocef 25 mg/ml intramammary suspension

25 milligram(s)/millilitre Intramammary suspension

Zoetis Belgium S.A.VPA10387/047/001

Main Information

Trade NamePathocef 25 mg/ml intramammary suspension
Active SubstancesCefoperazone
Strength25 milligram(s)/millilitre
Dosage FormIntramammary suspension
Licence HolderZoetis Belgium S.A.
Licence NumberVPA10387/047/001

Group Information

ATC CodeQJ51DA32 ZZZ Cefoperazon
Therapeutic ClassAntibacterial


Licence Issued04/04/2014
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportPDF Version
« Back